Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Acromegaly Market CAGR Outlook And Future Development
The acromegaly market has experienced rapid expansion in recent years. It is projected to increase from $2.56 billion in 2025 to $3.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.5%. The growth observed in the past can be attributed to various elements, including the limited availability of acromegaly diagnostic tools, an increasing prevalence of growth hormone disorders, the expansion of hospital and specialty clinic infrastructure, the adoption of conventional treatment methods, and a growing awareness of rare endocrine disorders.
The acromegaly market is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $5.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This projected growth during the forecast timeframe is primarily driven by the advancement of sophisticated somatostatin analogues, an increase in parenteral treatment availability, the growing embrace of precision medicine techniques, the expansion of homecare and outpatient treatment paradigms, and the incorporation of digital health and remote monitoring technologies. Significant trends anticipated in this period encompass a greater acceptance of growth hormone measurement and IGF-I testing, an increased application of somatostatin analogues and dopamine agonists, the broadening scope of minimally invasive surgery and radiation therapy, an intensifying emphasis on tailored patient treatment strategies, and improved awareness and initiatives for early detection.
Get A Free Sample Report With In-Depth Market Insights:
Acromegaly Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing incidence of hormonal conditions, such as diabetes, is projected to accelerate the expansion of the acromegaly market. These hormonal diseases, also known as endocrine disorders, are medical issues caused by a malfunction in the endocrine system. Diabetes is recognized as one of the most widespread and significant hormonal diseases. Acromegaly, along with other endocrine disorders, can develop from an overproduction of certain hormones, including growth hormone or cortisol. Moreover, high amounts of growth hormone can impact insulin synthesis, potentially leading to insulin resistance or type 2 diabetes mellitus in roughly 50% of individuals with acromegaly. For instance, in March 2024, the Office for Health Improvement and Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the proportion of people with type 1 diabetes receiving all eight recommended care processes grew by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels reached 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Hence, the rising number of hormonal diseases is propelling the growth of the acromegaly market.
Acromegaly Market Segment Landscape And Growth Outlook
The acromegaly market covered in this report is segmented –
1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis
3) By Route Of Administration: Oral, Parental, Other Routes Of Administration
4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments
5) By End Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess
Acromegaly Market Innovation Trends Shaping Future Development
Companies operating within the acromegaly market are actively pursuing the development of innovative products and solutions, such as generic lanreotide, to broaden treatment options and enhance patient outcomes. Generic lanreotide refers to a non-branded formulation of a medication used to treat acromegaly and certain neuroendocrine tumors. It functions as a somatostatin analogue, effectively reducing growth hormone secretion and improving patient accessibility to viable treatment choices. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. This injectable suspension, octreotide acetate, is indicated for addressing acromegaly and severe diarrhea associated with carcinoid syndrome. Its introduction significantly improves access to crucial therapy for patients requiring these treatments.
Acromegaly Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc , Strongbridge Biopharma plc, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.
View The Full Acromegaly Market Report:
Acromegaly Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the acromegaly market in 2025. The regions covered in the acromegaly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.